On Monday, Shares of Active Power, Inc. (NASDAQ:ACPW), subtract -12.64% and closed at $0.242 in the last trading session. The last trading range of the stock ranges between $0.23 and $0.30. Active Power ( NASDAQ : ACPW ) (“Company”), a manufacturer of flywheel energy storage products and modular infrastructure solutions (MIS), recently declared that it has signed an Asset Purchase Agreement (APA) with Langley Holdings PLC (“Langley”). Under the terms of the APA, Langley will acquire substantially all assets and operations of Active Power, counting the Active Power name, through their Piller USA Inc. partner for a nominal purchase price, plus the assumption of all debt, liabilities, customer, employee and purchase commitments going forward. Closing is subject to customary conditions and to the approval of the stockholders of Active Power. Closing is expected to occur in the fourth quarter of 2016.
Anheuser Busch Inbev SA (ADR)(NYSE:BUD), dropped -1.90% and closed at $128.91 in the last trading session. The last trading range of the stock ranges between $128.86 and $130.47. The company’s Market capitalization is $206.81 Billion with the total Outstanding Shares of 1.61 Billion. Anheuser-Busch InBev SA/NV, a brewing company, engages in the production, distribution, and sale of beer, alcoholic beverages, and soft drinks worldwide. It offers a portfolio of about 200 beer brands, counting Budweiser, Corona, Stella Artois, Becks, Leffe, Hoegaarden, Bud Light, Skol, Brahma, Antarctica, Quilmes, Victoria, Modelo Especial, Michelob Ultra, Harbin, Sedrin, Klinskoye, Sibirskaya Korona, Chernigivske, Cass, and Jupiler.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), gained 1.32% and closed at $12.24 in the last trading session. The last trading range of the stock ranges between $11.82 and $12.25. During the 52-week trading session the minimum price at which share price traded, registered at $6.96 and reached to max level of $18.65. Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The companys products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that facilitates the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, in addition to small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and other cancers in combination with various cancer therapies.